Tumor Cytobiology of IGF-1R In Breast Tumor Activation and Propagation; And the Role of Celecoxib in Its Inhibition

The Insulin-like Growth Factor 1 Receptor (IGF-1R) stands as a central orchestrator in cellular signaling, governing pivotal processes encompassing growth, proliferation, and differentiation. Its aberrant activation is intricately intertwined with the pathogenesis and progression of breast cancer, a heterogeneous disease presenting formidable clinical challenges. Amidst the burgeoning landscape of therapeutic interventions, Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), has emerged as a promising candidate for targeting the dysregulated IGF-1R pathway. This review delineates the intricate molecular mechanisms underlying Celecoxib's modulation of the IGF-1R pathway, elucidating its pharmacokinetic properties and therapeutic implications in breast cancer management. Celecoxib exerts inhibitory effects on IGF-1R through multifaceted molecular interactions, impeding receptor activation and downstream signaling cascades pivotal for tumor proliferation and metastasis. Furthermore, it regulates IGF-1R expression at both transcriptional and translational levels, exerting nuanced control over cellular responses. Moreover, Celecoxib's therapeutic impact transcends mere IGF-1R inhibition, as it potentiates pro-apoptotic pathways and disrupts tumor-permissive microenvironments. A nuanced understanding of Celecoxib's pharmacokinetic profile is imperative, considering its sustained and targeted inhibition of IGF-1R signaling, and its potential synergistic effects in combinatorial therapeutic regimens for breast cancer. This comprehensive elucidation underscores the paramount importance of deciphering Celecoxib's intricate molecular interplay with the IGF-1R pathway, heralding novel avenues for precision medicine and tailored therapeutic interventions in the management of breast cancer.